(Press-News.org) DURHAM, N.C. – Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 (“I Am Study”) at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and feasibility of an integrated multicomponent strategy to enhance daily oral HIV pre-exposure prophylaxis (PrEP) uptake and adherence among transgender women in a randomized immediate versus deferred design. The integrated care strategy included the provision of gender-affirming hormone therapy (GAHT) and co-located structured peer health navigation sessions (PHN) along with oral PrEP. Participants in the deferred arm received case management and referral to GAHT. Once participants reached week 26, they all received the integrated care strategy. The primary outcome measured at week 26 showed an increase in PrEP uptake and an encouraging level of PrEP adherence; however, PrEP uptake and adherence levels were the same between study arms.
“Overall peer support and providing access to GAHT and other needed services in both study arms likely led to an increase in PrEP engagement among study participants, highlighting the critical need for these supports in this population,” said Dr. Tonia Poteat, HPTN 091 protocol chair, professor at the Duke University School of Nursing, and associate director of the Duke Center for AIDS Research in Durham, N.C.
The study enrolled 304 transgender women aged 18 and older at four U.S. HPTN research sites (Houston, New York, Philadelphia, and San Francisco) and one Brazil site (Rio de Janeiro). Participants were randomized 1:1 to the immediate versus deferred intervention arm. U.S. participants in both study arms were offered Truvada® (tenofovir/emtricitabine) or Descovy® (emtricitabine and tenofovir alafenamide) for HIV PrEP starting at enrollment. Participants in Brazil were offered Truvada®, in keeping with the nationally approved and available PrEP product. Apretude® (cabotegravir) was unavailable at the time of the study’s initiation and, therefore, not included as one of the PrEP options.
At enrollment, participants in the immediate intervention arm received GAHT and co-located structured PHN. Participants in the deferred intervention arm received external GAHT and case management up to Week 26, then transitioned to the integrated strategy afterward. PrEP uptake and adherence were evaluated as the primary study outcome at week 26, with adherence defined as taking four or more pills per week based on tenofovir detection in dried blood spots.
“Transgender women have one of the highest HIV prevalence of any population yet continue to struggle to access and adhere to PrEP,” said Dr. Wafaa El-Sadr, HPTN co-principal investigator, director of ICAP, and professor of epidemiology and medicine at Columbia University in New York. “Tailoring strategies to address the unique needs of this population is critical to addressing this challenge.”
At enrollment, 11 percent of participants self-reported PrEP use, and 42 percent reported GAHT use. At week 26, PrEP uptake was 85 percent and 87 percent in the immediate and deferred study arms, respectively. PrEP adherence based on dried blood spot results was confirmed for 50 percent and 51 percent of the participants, respectively. Retention was comparably high in both study arms (84 percent and 87 percent, respectively).
“Meaningful involvement of the transgender community through the provision of peer-delivered case management and access to needed services was important to increasing PrEP engagement among all study participants,” said Dr. Myron Cohen, HPTN co-principal investigator, and director of the Institute for Global Health at the University of North Carolina in Chapel Hill. “This approach offers a path to reducing HIV acquisition in this population.”
About HPTN
The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community members, and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. The U.S. National Institute of Allergy and Infectious Diseases, the U.S. National Institute of Mental Health, Office of The Director, the U.S. National Institute on Drug Abuse, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, all part of the U.S. National Institutes of Health, co-fund the HPTN. The HPTN has collaborated with more than 68 clinical research sites in 13 countries to evaluate new HIV prevention interventions and strategies in populations with a disproportionate HIV burden. The HPTN research agenda – more than 62 trials ongoing or completed with over 175,000 participants enrolled and evaluated – is focused primarily on discovering new HIV prevention tools and evaluating integrated strategies, including biomedical interventions combined with behavioral risk reduction interventions and structural interventions. For more information, visit hptn.org.
END
HPTN 091 study shows encouraging uptake and adherence to oral PrEP among transgender women
2024-10-10
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Gonzalez receives award to study causes of racial disparities in amputation rates in Indiana
2024-10-10
INDIANAPOLIS --More than 8 million people, ages 40 and older, living in the U.S. are affected by peripheral arterial disease, a lifelong medical condition and the most common cause of limb amputation in the country. A data scientist, health services researcher and vascular surgeon who studies health equity, Andrew A. Gonzalez, M.D., J.D., MPH, of the Regenstrief Institute and the Indiana University School of Medicine, has received a 2024 Ralph W. and Grace M. Showalter Research Trust award to conduct a new study, Exploring Causes of Racial Disparities in Amputation Rates in Indiana.
Dr. ...
Mount Sinai opens state-of-the-art center for patients with complex conditions including Lyme disease and long COVID
2024-10-10
Mount Sinai’s Department of Rehabilitation and Human Performance has announced the grand opening of the Cohen Center for Recovery From Complex Chronic Illnesses (CoRE), providing clinical care for patients with conditions such as long Lyme disease/Lyme+, long COVID, and other infection-associated complex chronic illnesses such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Ehlers-Danlos syndrome (EDS).
Supported by philanthropy from various donors, including an inaugural gift from Beth and ...
$14M NIH grant funds gene-editing research for rare metabolic diseases at Penn and CHOP
2024-10-10
PHILADELPHIA— A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children’s Hospital of Philadelphia (CHOP). The research will focus specifically on developing therapies for urea cycle disorders, which impact roughly 1 in every 35,000 children. Using a form of CRISPR technology, the ultimate vision of the four-year grant is to create a platform for rapid development of personalized gene-editing therapies for ...
One experiment: The brain’s landscapers
2024-10-10
Imagine yourself sometime in the far future aboard a routine rocket to Mars. Someone just spilled their drink. Without gravity, it collects in floating blobs that ripple right before your eyes. Now freeze.
What you see might look something like the above image from Cold Spring Harbor Laboratory’s (CSHL’s) Cheadle lab. But those purple and green blobs aren’t the floating remains of somebody’s drink. They’re mysterious cells in the brain’s visual cortex called OPCs.
The visual cortex processes everything we see. Incoming visual information is ...
AI-supported dermatology: Now for darker skin tones too, thanks to a new data set
2024-10-10
In many countries in Africa, up to nine out of ten children suffer from a skin problem, and there are far too few local dermatologists. Artificial intelligence could help with diagnosis, but needs to be trained with the relevant images, so researchers have created a new data set for dark skin tones.
Demand is high, the lack of dermatologists acute: in many countries in Africa, there is less than one dermatology specialist per one million people – compared to the World Health Organization (WHO) recommendation of ...
Understanding how smiling influences relationship building during real-life conversations
2024-10-10
Smiling during conversations creates warmth, making people feel more comfortable and connected. For example, a friendly smile when meeting someone new can ease nervousness. A smile can soften tension in a debate, showing respect among the participants despite disagreement. In fact, extensive studies have been conducted in the past in an attempt to understand smiling interactions in a natural conversation. Despite these studies, however, little is known about the extent to which one’s smile influences or gets affected by the other person’s smile during a conversation.
A new study sought to investigate this by quantifying ...
British Heart Foundation Data Science Centre launches first open challenge to explore AI ECG potential
2024-10-10
The British Heart Foundation (BHF) Data Science Centre, led by Health Data Research UK, is hosting an open challenge which invites competitors to explore the potential of Artificial Intelligence to improve the use of electrocardiogram (ECG) for cardiovascular disease patient care. The challenge has been co-designed with members of public and patients affected by cardiovascular disease.
The BHF Data Science Centre is collaborating with experts from the University of Edinburgh to use a synthetic imaging dataset made up of approximately 20,000 simulated electrocardiogram (ECG) images. Competitors will be invited to develop algorithms which can make ...
Heart failure, atrial fibrillation & coronary heart disease linked to cognitive impairment
2024-10-10
Statement Highlights:
Previous studies have found that 14-81% of patients with heart failure experience some degree of cognitive impairment affecting language, memory or executive function.
Evidence also indicates that people with atrial fibrillation have a 39% increased risk of memory or thinking problems; adults with heart disease have a 27% higher risk of developing dementia; and up to 50% of individuals experience cognitive decline after a heart attack.
Managing heart health from an early age is important, not only for preventing heart disease but also for protecting brain health and reducing the risk of cognitive impairment in later life.
Embargoed until 4:00 a.m. CT/5:00 ...
To make children better fact-checkers, expose them to more misinformation — with oversight
2024-10-10
In an era when online misinformation is seemingly everywhere and objective facts are often in dispute, UC Berkeley psychologists in a new study have presented a somewhat paradoxical partial solution: Expose young children to more misinformation online — not less.
Doing so in limited circumstances, and with careful oversight and education, can help children gain the tools they'll need to sort fact from fiction online, said Evan Orticio, a Ph.D. student in UC Berkeley’s Department of Psychology and lead author of a paper published today ...
Renowned psychiatrist professor Celso Arango advocates for primary prevention in mental health
2024-10-10
In a revealing Genomic Press Interview published in Brain Medicine on October 10, 2024, Professor Celso Arango, a prominent psychiatrist and researcher, outlines his vision for the future of mental health care. Professor Arango, who serves as Director of the Institute of Psychiatry and Mental Health at Hospital General Universitario Gregorio Marañón and Professor of Psychiatry at the Universidad Complutense de Madrid, advocates for a paradigm shift towards primary prevention in psychiatry.
Professor Arango's career trajectory, from his early exposure to ...